Yahoo Finance analysis suggests that in 2026, traditional pharmaceutical giant Amgen is a more stable investment choice compared to gene-editing pioneer CRISPR Therapeutics.

The report indicates that Amgen's revenue for fiscal year 2025 was nearly $36.7 billion, a year-over-year increase of approximately 9.9%, with a net profit of nearly $7.7 billion and a net profit margin of about 21%. In contrast, CRISPR Therapeutics' revenue for the same period was approximately $3.5 million, a year-over-year decrease of about 90%, with a net loss of nearly $581.6 million and a net profit margin of approximately -16,569.8%.

The analysis suggests that despite CRISPR Therapeutics' gene-editing therapy CASGEVY having received approval in multiple regions and experiencing accelerating revenue growth, it remains in a significant loss-making state, with its investment outlook highly dependent on commercial execution and R&D success. In comparison, Amgen's business is more stable and predictable, with several products achieving double-digit growth, an upward revision of its full-year performance outlook, and continuous dividend payouts, enabling it to better cope with competitive pressures from older drugs.